NL300650I2 - Olodaterol, het R-enantiomeer daarvan, mengsels van isomeren daarvan, zuuradditiezouten met farmacologisch aanvaardbare zuren daarvan, evenals solvaten en/of hydraten daarvan, in het bijzonder Olodaterol en Olodaterolhydrochloride - Google Patents
Olodaterol, het R-enantiomeer daarvan, mengsels van isomeren daarvan, zuuradditiezouten met farmacologisch aanvaardbare zuren daarvan, evenals solvaten en/of hydraten daarvan, in het bijzonder Olodaterol en OlodaterolhydrochlorideInfo
- Publication number
- NL300650I2 NL300650I2 NL300650C NL300650C NL300650I2 NL 300650 I2 NL300650 I2 NL 300650I2 NL 300650 C NL300650 C NL 300650C NL 300650 C NL300650 C NL 300650C NL 300650 I2 NL300650 I2 NL 300650I2
- Authority
- NL
- Netherlands
- Prior art keywords
- olodaterol
- enantiomer
- solvates
- hydrates
- isomers
- Prior art date
Links
- COUYJEVMBVSIHV-SFHVURJKSA-N olodaterol Chemical compound C1=CC(OC)=CC=C1CC(C)(C)NC[C@H](O)C1=CC(O)=CC2=C1OCC(=O)N2 COUYJEVMBVSIHV-SFHVURJKSA-N 0.000 title 3
- 239000002253 acid Substances 0.000 title 2
- 229960004286 olodaterol Drugs 0.000 title 2
- 150000007513 acids Chemical class 0.000 title 1
- 150000004677 hydrates Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 title 1
- 229960001733 olodaterol hydrochloride Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 239000012453 solvate Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10253282A DE10253282A1 (de) | 2002-11-15 | 2002-11-15 | Neue Arzneimittel zur Behandlung von chronisch obstruktiver Lungenerkrankung |
| PCT/EP2003/012565 WO2004045618A2 (de) | 2002-11-15 | 2003-11-11 | Neue arzneimittel zur behandlung von chronisch obstruktiver lungenerkrankung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NL300650I2 true NL300650I2 (nl) | 2017-11-02 |
Family
ID=32185709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NL300650C NL300650I2 (nl) | 2002-11-15 | 2014-03-07 | Olodaterol, het R-enantiomeer daarvan, mengsels van isomeren daarvan, zuuradditiezouten met farmacologisch aanvaardbare zuren daarvan, evenals solvaten en/of hydraten daarvan, in het bijzonder Olodaterol en Olodaterolhydrochloride |
Country Status (38)
Families Citing this family (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7056916B2 (en) | 2002-11-15 | 2006-06-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Medicaments for the treatment of chronic obstructive pulmonary disease |
| GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| DE102004019539A1 (de) * | 2004-04-22 | 2005-11-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittel zur Behandlung von Atemwegserkrankungen |
| DK1781298T3 (da) | 2004-04-22 | 2012-05-07 | Boehringer Ingelheim Int | Lægemiddelkombinationer indeholdende benzoxazin til behandling af luftvejs-sygdomme |
| WO2005110990A1 (de) * | 2004-05-13 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Hydroxy-substituierte benzkondensierte heterozyklen als betaagonisten zur behandlung von atemwegserkrankungen |
| US7220742B2 (en) | 2004-05-14 | 2007-05-22 | Boehringer Ingelheim International Gmbh | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments |
| US20050256115A1 (en) * | 2004-05-14 | 2005-11-17 | Boehringer Ingelheim International Gmbh | Aerosol formulation for the inhalation of beta-agonists |
| DE102004024453A1 (de) * | 2004-05-14 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen |
| DE102004024451A1 (de) * | 2004-05-14 | 2005-12-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulverformulierungen für die Inhalation, die Enantiomerenreine Betaagonisten enthalten |
| DE102004024454A1 (de) * | 2004-05-14 | 2005-12-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| US7745621B2 (en) | 2004-05-14 | 2010-06-29 | Boehringer Ingelheim International Gmbh | Long acting bronchodilators for the treatment of respiratory diseases |
| DE102004024452A1 (de) * | 2004-05-14 | 2005-12-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aerosolformulierung für die Inhalation von Betaagonisten |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| DE102004045648A1 (de) * | 2004-09-21 | 2006-03-23 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Betamimetika zur Behandlung von Atemwegserkrankungen |
| GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| DE102005007654A1 (de) * | 2005-02-19 | 2006-08-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen |
| GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| DE102005030733A1 (de) * | 2005-07-01 | 2007-01-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff |
| GB0516313D0 (en) | 2005-08-08 | 2005-09-14 | Argenta Discovery Ltd | Azole derivatives and their uses |
| US7994211B2 (en) | 2005-08-08 | 2011-08-09 | Argenta Discovery Limited | Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses |
| MX2008001976A (es) * | 2005-08-15 | 2008-03-25 | Boehringer Ingelheim Int | Procedimiento para la preparacion de betamimeticos. |
| US20070086957A1 (en) * | 2005-10-10 | 2007-04-19 | Thierry Bouyssou | Combination of medicaments for the treatment of respiratory diseases |
| TWI389692B (zh) | 2005-10-10 | 2013-03-21 | Boehringer Ingelheim Int | 用以吸入β-共效劑的氣溶膠調配物 |
| JP5006330B2 (ja) | 2005-10-21 | 2012-08-22 | ノバルティス アーゲー | Ｉｌ１３に対するヒト抗体および治療的使用 |
| AU2006311060A1 (en) * | 2005-11-09 | 2007-05-18 | Boehringer Ingelheim International Gmbh | Aerosolformulation for inhalation |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| JP2009526817A (ja) * | 2006-02-16 | 2009-07-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器疾患の治療用医薬組成物 |
| PE20080142A1 (es) | 2006-03-15 | 2008-04-14 | Boehringer Ingelheim Int | Beta-agonistas enantiomericamente puros y sus procedimientos de preparacion |
| WO2007121920A2 (en) | 2006-04-21 | 2007-11-01 | Novartis Ag | Purine derivatives for use as adenosin a2a receptor agonists |
| JP2010500319A (ja) * | 2006-08-07 | 2010-01-07 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 鏡像体上純粋な新規ベータアゴニスト、それらの製造方法及び医薬としてのそれらの使用 |
| UY30542A1 (es) * | 2006-08-18 | 2008-03-31 | Boehringer Ingelheim Int | Formulacion de aerosol para la inhalacion de agonistas beta |
| UY30543A1 (es) * | 2006-08-18 | 2008-03-31 | Boehringer Ingelheim Int | Formulacion de aerosol para la inhalacion de beta- agonistas |
| KR20090073121A (ko) | 2006-09-29 | 2009-07-02 | 노파르티스 아게 | Ｐｉ3ｋ 지질 키나제 억제제로서의 피라졸로피리미딘 |
| CA2667962A1 (en) | 2006-10-30 | 2008-05-08 | Novartis Ag | Heterocyclic compounds as antiinflammatory agents |
| DK2104535T3 (da) | 2007-01-10 | 2011-04-04 | Irm Llc | Forbindelser og sammensætninger som kanalaktiverende proteaseinhibitorer |
| PL2125759T3 (pl) * | 2007-01-25 | 2011-12-30 | Boehringer Ingelheim Int | Sposób wytwarzania związków betamimetycznych |
| CN101687851B (zh) | 2007-05-07 | 2013-02-27 | 诺瓦提斯公司 | 有机化合物 |
| EA017919B1 (ru) | 2007-12-10 | 2013-04-30 | Новартис Аг | Производные пиразин-2-карбоксамида для лечения заболеваний, которые поддаются лечению путем блокирования эпителиальных натриевых каналов |
| CN101910153B (zh) | 2008-01-11 | 2014-01-22 | 诺华股份有限公司 | 作为激酶抑制剂的嘧啶类 |
| EA201001848A1 (ru) | 2008-06-10 | 2011-08-30 | Новартис Аг | Производные пиразина в качестве блокаторов эпителиальных натриевых каналов |
| US8236786B2 (en) | 2008-08-07 | 2012-08-07 | Pulmagen Therapeutics (Inflammation) Limited | Respiratory disease treatment |
| SI2379507T1 (sl) | 2008-12-30 | 2014-02-28 | Pulmagen Therapeutics (Inflammation) Limited | Spojine sulfonamida za zdravljenje respiratornih motenj |
| JP2012516345A (ja) | 2009-01-29 | 2012-07-19 | ノバルティス アーゲー | 星細胞腫治療用置換ベンゾイミダゾール |
| WO2010150014A1 (en) | 2009-06-24 | 2010-12-29 | Pulmagen Therapeutics (Inflammation) Limited | 5r- 5 -deuterated glitazones for respiratory disease treatment |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| EA201200260A1 (ru) | 2009-08-12 | 2012-09-28 | Новартис Аг | Гетероциклические гидразоны и их применение для лечения рака и воспаления |
| UA111579C2 (uk) | 2009-08-17 | 2016-05-25 | Інтеллікіне Ллк | ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ |
| JP2013508414A (ja) | 2009-10-22 | 2013-03-07 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症および他の慢性疾患の治療のための組成物 |
| GB0918923D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminothiazole derivatives |
| GB0918922D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Aminopyridine derivatives |
| GB0918924D0 (en) | 2009-10-28 | 2009-12-16 | Vantia Ltd | Azaindole derivatives |
| WO2011098746A1 (en) | 2010-02-09 | 2011-08-18 | Pulmagen Therapeutics (Inflammation) Limited | Crystalline acid addition salts of ( 5r) -enanti0mer of pioglitazone |
| GB201002224D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| GB201002243D0 (en) | 2010-02-10 | 2010-03-31 | Argenta Therapeutics Ltd | Respiratory disease treatment |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
| WO2012040082A2 (en) * | 2010-09-21 | 2012-03-29 | Intekrin Therapeutics, Inc. | Antidiabetic solid pharmaceutical compositions |
| US20130324526A1 (en) | 2011-02-10 | 2013-12-05 | Novartis Ag | [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
| EP2678016B1 (en) | 2011-02-23 | 2016-08-10 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
| SG192795A1 (en) | 2011-02-25 | 2013-09-30 | Irm Llc | Compounds and compositions as trk inhibitors |
| UY34305A (es) | 2011-09-01 | 2013-04-30 | Novartis Ag | Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar |
| AU2012310168B2 (en) | 2011-09-15 | 2015-07-16 | Novartis Ag | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase |
| CN103946221B (zh) | 2011-09-16 | 2016-08-03 | 诺华股份有限公司 | 用于治疗囊性纤维化的杂环化合物 |
| WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
| WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
| US9056867B2 (en) | 2011-09-16 | 2015-06-16 | Novartis Ag | N-substituted heterocyclyl carboxamides |
| US9174994B2 (en) | 2011-11-23 | 2015-11-03 | Intellikine, Llc | Enhanced treatment regimens using mTor inhibitors |
| US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
| KR102115047B1 (ko) | 2012-04-03 | 2020-05-26 | 노파르티스 아게 | 티로신 키나제 억제제들을 갖는 조합 제품 및 그의 용도 |
| WO2014056840A1 (en) | 2012-10-09 | 2014-04-17 | Boehringer Ingelheim International Gmbh | Beta-2-adrenoceptor agonist for the treatment of cough |
| US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
| CN105246482A (zh) | 2013-03-15 | 2016-01-13 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
| TW201605450A (zh) | 2013-12-03 | 2016-02-16 | 諾華公司 | Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途 |
| BR112016024533A8 (pt) | 2014-04-24 | 2021-03-30 | Novartis Ag | derivados de amino pirazina como inibidores de fosfatidilinositol 3-cinase ou sal, seu uso, e composição e combinação farmacêuticas |
| WO2015162461A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
| KR20160145780A (ko) | 2014-04-24 | 2016-12-20 | 노파르티스 아게 | 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체 |
| WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
| WO2016016822A1 (en) | 2014-07-31 | 2016-02-04 | Novartis Ag | Combination therapy |
| US20200069679A1 (en) | 2016-12-12 | 2020-03-05 | Boehringer Ingelheim International Gmbh | Nintedanib for use in methods for the treatment of interstitial lung diseases by coadministration with oladaterol |
| JP7116060B2 (ja) | 2016-12-20 | 2022-08-09 | インケ、ソシエダ、アノニマ | Ｒ－６－ヒドロキシ－８－［１－ヒドロキシ－２－［２－（４－メトキシフェニル）－１，１－ジメチルエチルアミノエチル］－２ｈ－１，４－ベンゾオキサジン－３（４ｈ）－オン塩酸塩の改良された製造法 |
| CN109096218B (zh) * | 2018-08-06 | 2020-10-27 | 上海方予健康医药科技有限公司 | 盐酸奥达特罗晶型a及其制备方法 |
| CN108997248B (zh) * | 2018-08-06 | 2023-08-01 | 上海方予健康医药科技有限公司 | 盐酸奥达特罗晶型b及其制备方法 |
| BR112021024668A2 (pt) | 2019-06-10 | 2022-05-31 | Novartis Ag | Derivado de piridina e pirazina para o tratamento de fc, dpoc e bronquiectasia |
| KR20220052934A (ko) | 2019-08-28 | 2022-04-28 | 노파르티스 아게 | 치환 1,3-페닐 헤테로아릴 유도체 및 질환 치료에서의 이의 용도 |
| US11304897B2 (en) | 2020-06-09 | 2022-04-19 | Anovent Pharmaceutical (U.S.), Llc | Pharmaceutical formulation containing umeclidinium bromide and vilanterol trifenatate |
| US11331322B1 (en) | 2021-09-15 | 2022-05-17 | Santen Pharmaceutical Co., Ltd. | Medicament for preventing and/or treating dry eye |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3134590A1 (de) * | 1981-09-01 | 1983-03-10 | Boehringer Ingelheim KG, 6507 Ingelheim | Neue benzo-heterocyclen |
| US4460581A (en) * | 1982-10-12 | 1984-07-17 | Boehringer Ingelheim Kg | (1-Hydroxy-2-amino-alkyl)-substituted benzoxazinones and benzoxazolinones |
| DE3743265A1 (de) * | 1987-12-19 | 1989-06-29 | Boehringer Ingelheim Kg | Neue ammoniumverbindungen, ihre herstellung und verwendung |
| SK15382002A3 (sk) * | 2000-04-27 | 2003-03-04 | Boehringer Ingelheim Pharma Kg | Betamimetiká, farmaceutický prostriedok s ich obsahom a ich použitie |
-
2002
- 2002-11-15 DE DE10253282A patent/DE10253282A1/de not_active Withdrawn
-
2003
- 2003-11-11 PT PT03778312T patent/PT1562603E/pt unknown
- 2003-11-11 EP EP03778312.3A patent/EP1562603B3/de not_active Expired - Lifetime
- 2003-11-11 JP JP2004552561A patent/JP4317138B2/ja not_active Expired - Lifetime
- 2003-11-11 KR KR1020057008679A patent/KR101092247B1/ko not_active Expired - Lifetime
- 2003-11-11 SI SI200331634T patent/SI1562603T1/sl unknown
- 2003-11-11 CA CA2506082A patent/CA2506082C/en not_active Expired - Lifetime
- 2003-11-11 NZ NZ540661A patent/NZ540661A/en not_active IP Right Cessation
- 2003-11-11 PL PL375270A patent/PL212238B1/pl unknown
- 2003-11-11 DE DE50311502T patent/DE50311502D1/de not_active Expired - Lifetime
- 2003-11-11 CN CN200910266327A patent/CN101735166A/zh active Pending
- 2003-11-11 RS YU20050361A patent/RS51607B/sr unknown
- 2003-11-11 ES ES03778312.3T patent/ES2326878T7/es active Active
- 2003-11-11 BR BRPI0316264A patent/BRPI0316264B8/pt active IP Right Grant
- 2003-11-11 CN CN201010004697A patent/CN101817800A/zh active Pending
- 2003-11-11 AT AT03778312T patent/ATE430569T1/de active
- 2003-11-11 EA EA200500715A patent/EA008665B1/ru active Protection Beyond IP Right Term
- 2003-11-11 HR HR20050432A patent/HRP20050432B1/xx not_active IP Right Cessation
- 2003-11-11 ME MEP-2008-536A patent/ME00354B/me unknown
- 2003-11-11 WO PCT/EP2003/012565 patent/WO2004045618A2/de not_active Ceased
- 2003-11-11 UA UAA200505926A patent/UA81276C2/uk unknown
- 2003-11-11 EP EP08169872A patent/EP2025338A1/de not_active Withdrawn
- 2003-11-11 CN CNA2003801030945A patent/CN1713914A/zh active Pending
- 2003-11-11 AU AU2003285326A patent/AU2003285326B2/en active Active
- 2003-11-11 DK DK03778312T patent/DK1562603T3/da active
- 2003-11-11 MX MXPA05005081A patent/MXPA05005081A/es active IP Right Grant
- 2003-11-13 PE PE2003001147A patent/PE20040694A1/es active IP Right Grant
- 2003-11-13 MY MYPI20034360A patent/MY136034A/en unknown
- 2003-11-14 AR ARP030104201A patent/AR041969A1/es not_active Application Discontinuation
- 2003-11-14 TW TW092132031A patent/TWI343812B/zh active
-
2005
- 2005-03-17 ZA ZA2005/02246A patent/ZA200502246B/en unknown
- 2005-04-07 IL IL167900A patent/IL167900A/en active Protection Beyond IP Right Term
- 2005-05-02 EC EC2005005774A patent/ECSP055774A/es unknown
- 2005-06-14 NO NO20052883A patent/NO334314B1/no not_active IP Right Cessation
- 2005-06-14 CO CO05057641A patent/CO5570670A2/es not_active Application Discontinuation
-
2009
- 2009-08-04 CY CY20091100826T patent/CY1110500T1/el unknown
-
2012
- 2012-07-19 AR ARP120102613A patent/AR087241A2/es unknown
-
2014
- 2014-02-27 BE BE2014C016C patent/BE2014C016I2/fr unknown
- 2014-03-06 LT LTPA2014012C patent/LTC1562603I2/lt unknown
- 2014-03-07 NL NL300650C patent/NL300650I2/nl unknown
- 2014-03-07 HU HUS1400011C patent/HUS1400011I1/hu unknown
- 2014-03-10 NO NO2014005C patent/NO2014005I1/no unknown
- 2014-04-22 LU LU92433C patent/LU92433I2/fr unknown
- 2014-06-23 FR FR14C0049C patent/FR14C0049I2/fr active Active
- 2014-08-13 CY CY2014032C patent/CY2014032I1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL300650I2 (nl) | Olodaterol, het R-enantiomeer daarvan, mengsels van isomeren daarvan, zuuradditiezouten met farmacologisch aanvaardbare zuren daarvan, evenals solvaten en/of hydraten daarvan, in het bijzonder Olodaterol en Olodaterolhydrochloride | |
| IS7483A (is) | Bensamíðafleiður gagnlegar sem históndeasetýlasatálmar | |
| PL374542A1 (en) | Benzofused heteroaryl amide derivatives of thienopyridines useful as therapeutic agents, pharmaceutical compositions including the same, and methods for their use | |
| IL190032A0 (en) | Amide and carbamate derivatives of alkyl substituted n-[4-(4-amino-1h-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamides and methods | |
| ME02688B (me) | Hinazolinoni kao inhibitori humane fosfatidilinozitol 3 - kinaze delta | |
| DK1527050T3 (da) | Quinolin-derivater og deres anvendelse som mycobakterielle inhibitorer | |
| IL190198A0 (en) | N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors | |
| DK1648426T3 (da) | Benzimidazolderivater og anvendelse heraf som proteinkinaseinhibitorer | |
| SI1877379T1 (sl) | Derivati hidroksibenzinamida in njih uporaba kot inhibitorji HSP90 | |
| NO20054969D0 (no) | 2-cyanopropansyreamid- og esterderivater og deres anvendelse | |
| AU2003206787A8 (en) | Sulfonate derivatives and the use therof as latent acids | |
| JP2007506758A5 (ja) | ４−（１−ベンゾフラン−３−イル−メチリデンアミノオキシ−プロポキシ）−安息香酸誘導体および線溶系の障害、血栓症の治療用のｐａｉ−１阻害剤としての関連化合物 | |
| IS7575A (is) | Própíónsýruafleiður og notkun þeirra sem HPPAR virkjar | |
| DK1581518T3 (da) | Substituerede 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazin-derivater og deres anvendelse som neurokinin antagonister | |
| IL172542A0 (en) | 2-hydroxymethyl-3,4,5-trihydroxy-1-benzilpiperidine derivatives as inhibitors of glucosylceramide | |
| IL197887A0 (en) | New fluorene derivatives, compositions containing the same and use thereof as inhibitors of the protein chaperone hsp 90 | |
| EA200801875A1 (ru) | Антагонист cd 80 | |
| IL169337A0 (en) | Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists | |
| AU2003215677A1 (en) | N-(morpholin-2yl) methyl acetamide derivatives as ccr-3 antagonists useful in the treatment of inflammatory diseases | |
| IL172840A (en) | Benzimidazole history and their use as a protein kinase inhibitor | |
| ITMI20020247V0 (it) | Dispositivo perfezionato per la realizzazione di ante per mobili | |
| ITMI20022626A1 (it) | Inibitori di polimerizzazione e loro impiego pre prevenire la | |
| ITFI20050186A1 (it) | Procedimento e attrezzatura per la marmorizzazione di manufatti in cemento | |
| IL186147A0 (en) | Hydroxybenzamide derivatives and their use as inhibitors of hsp90 | |
| DOP2004000980A (es) | [1,8] naftiridin-2- onas y compuestos relacionados para el tratamiento de la esquizofrenia |